NCT04349228

Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals

Assessment of the Efficacy and Safety of Hydroxychloroquine (HCQ) Administered as a Prophylaxis for Health Professionals Exposed to COVID19 and Working in Medical Intensive Care Units, in Tunisia. Multicentric Randomized Comparative Study

• Status: Withdrawn
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Abderrahmane Mami Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

Assessment of the Efficacy and Safety of Hydroxychloroquine (HCQ) Administered as a Prophylaxis for Health Professionals Exposed to COVID19 and Working in Medical Intensive Care Units, in Tunisia. Multicentric, Randomized Comparative Study

Detailed description

Interventional, Multicentric, Randomized Controlled Study in Two Parallel Groups of 530 Healthcare Professionals working in the Intensive Care Unit Exposed to Risk of COVID19 Infection Taking Hydroxychloroquine (HCQ) (200 mg/day) VS Placebo

Conditions

• COVID19
• Sars-CoV2
• Hydroxychloroquine
• Prophylaxis
• Healthcare Worker

Interventions

Type	Name	Description
DRUG	Hydroxychloroquine (HCQ)	Hydroxychloroquine (HCQ) 200mg/day
DRUG	Placebo oral tablet	Placebo of Hydroxychloroquine (HCQ) without any active substance

Timeline

• Start date: 2020-04-28
• Primary completion: 2020-07-15
• Completion: 2020-07-15
• First posted: 2020-04-16
• Last updated: 2020-08-28

Locations

1 site across 1 country: Tunisia